Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with pancreatic adenocarcinoma or adeno-squamous carcinoma (specific types of pancreatic cancer) that has spread to the liver, confirmed through tissue or cell testing.
• People whose cancer has spread to other parts of the body as well, as long as it has not spread to the brain.
• People whose cancer has come back or spread after surgery and follow-up treatment, where doctors have a strong suspicion based on scans (MRI or CT) and/or a blood marker called CA 19-9, even without a repeat biopsy — especially if a repeat biopsy would be unsafe or very difficult.
• People who have not yet had any treatment specifically for stage IV (advanced, spread) pancreatic cancer.
• People who previously received chemotherapy or combined chemotherapy and radiation before or after surgery may still be considered (confirm with trial site for specific timing rules based on the type of chemotherapy received).
• People aged 18 or older.
• People whose blood test results meet specific levels for blood cell counts, liver function, and kidney function (the trial site will assess these).
• People whose heart's electrical activity (measured by an ECG) falls within a specific range — men below 470 msec and women below 490 msec on a measurement called QTc.
• People with a life expectancy of at least 3 months.
• People who are considered physically well enough to carry out daily activities with no or minimal limitations (rated 0 or 1 on a standard medical scale called ECOG).
• People who are physically able to operate a specific medical device used in this trial, called the Novo TTF-100L(P) system.
• People whose cancer is measurable on scans according to standard criteria used in clinical trials.
• Women who could become pregnant must have a negative pregnancy blood test within 14 days before starting treatment, and both male and female participants who are sexually active must agree to use effective contraception throughout the trial and for 28 days after it ends.

Who may not be able to join:

• People who have already received treatment specifically for metastatic (advanced, spread) pancreatic cancer.
• People whose cancer has spread to the brain.
• People who have certain heart rhythm problems (2nd or 3rd degree heart block) that require a pacemaker.
• People who have a cardiac pacemaker or any other implanted electrical device in the chest or abdomen.
• People at significant risk of heart problems due to heart failure or a previous heart attack.
• People with serious other health conditions that the trial doctors believe would make participation unsuitable (confirm with trial site).
• People who are currently taking certain medications known to carry a specific serious heart rhythm risk (called Torsades de Pointes warning), unless those medications can be safely switched to a different drug.
• People who have a known sensitivity or allergy to conductive hydrogel (a type of gel used with the medical device in this trial).
• People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.